Polyphenon® E for the treatment of HPV infections
	Press releases from MediGene AG and partnering companies:
December 2011	MediGene: Veregen® Marketing Approval Process Initiated for 17 Additional European Countries
September 2011	MediGene and Pharmanova Sign Agreement for the Commercialization of Veregen® in a Number of Countries in Southeastern Europe
May 2011	MediGene Signs Veregen® Commercialization Agreement with SynCore Bio in Taiwan
April 2011	MediGene and Triton Pharma Sign Partnership Agreement for the Commercialization of Veregen® in Canada
March 2011	MediGene Announces Approval of Veregen® in Spain
March 2011	MediGene and Will-Pharma Sign Agreement for the Commercialization of Veregen® in Benelux
February 2011	MediGene and Pierre Fabre Sign Agreement for the Commercialization of Veregen® in Mexico, Central America, Venezuela and Colombia
January 2011	MediGene Adds Romania and Bulgaria to Existing Partnership Agreement with Meditrina for the Commercialization of Veregen®
January 2011	MediGene Concludes an Agreement with Laboratoires Expanscience for the Commercialization of Veregen® in France
May 2010	MediGene continues the global licensure of Veregen® through agreements with GC Rise in China and JS Bio Pharm in South Korea
April 2010	MediGene Signs Agreement with Meditrina for the Commercialization of Veregen® in Greece and Cyprus
February 2010	MediGene and Teva sign agreement to commercialize Veregen™ in Israel
September 2009	MediGene AG Receives Marketing Authorization for Veregen® in Germany
July 2009	MediGene receives Positive Assessment on Market Authorisation for Veregen® in First European Countries
June 2009	MediGene Concludes Agreement with Juste for the Commercialization of Veregen® in Spain and Portugal
April 2009	MediGene: USPTO Grants Extension of a Patent on Veregen®
November 2008	MediGene: European Patent Office decides to grant new European Patent for Veregen®
December 2007	Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% “Veregen™ is the first botanical drug approved for prescription use in the United States”
	MediGene’s Second Drug, Veregen™ (Polyphenon® E Ointment) Launched
April 2007	European Regulatory Authorities Accept MediGene’s Marketing Authorization Application for Polyphenon® E Ointment for Review
October 2006	MediGene AG Obtains Approval of Polyphenon® E Ointment in the USA
January 2006	Bradley Pharmaceuticals Enters Into Licensing Agreement With MediGene AG for POLYPHENON® E Ointment
	MediGene and Bradley Pharmaceuticals Enter Marketing and Development Partnership Polyphenon® E Ointment Bradley acquires US commercialization rights for genital warts and other dermatological diseases. MediGene retains full rest of world commercialization rights. Maximum milestone payments of up to $69 MM, including initial payment of $5 MM. Royalties on product sales Bradley Pharmaceuticals to support development costs for further indications.
December 2005	MediGene announces FDA Acceptance of New Drug Application for Polyphenon® E Ointment for the Treatment of Genital Warts
October 2005	MediGene Presents Results Obtained in Phase III Trial of Polyphenon® E Ointment Speech to be Given on the Occasion of the 14th Congress of the European Academy of Dermatology and Venerology in London
December 2004	MediGene Successfully Completes Pivotal Clinical Phase III Trials of Polyphenon® E Ointment for the Treatment of Genital Warts
March 2004	MediGene Achieves Positive Clinical Results With Polyphenon® E Ointment in European Phase 3 Trial
February 2004	MediGene: Patient Recruitment for Final Phase 3 Clinical Trial of Polyphenon® E Ointment Completed as Scheduled This allows completion of the trial by the end of the year, as planned
September 2003	MediGene acquires patents on Polyphenon® E for further indications
Back :: Licensed Products :: Current Research :: Management :: Contact :: Home
Veregen® is a registered trademark of MediGene AG. Polyphenon® is a registered trademark of Mitsui Norin Co., Ltd.